AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37486082 — intervention group
Group type: COMPARATOR
Intervention: V122I carriers without ATTR-CM
Number of subjects: 278
Study 37486082 — intervention group
Group type: COMPARATOR
Intervention: HF controls
Number of subjects: 278
Study 37486184 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-minute step test (2MST)
Number of subjects: 51
Study 37486343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (PARP inhibitor)
Number of subjects: 42
Study 37486343 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy after PARPi progression
Number of subjects: 42
Study 37486343 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy after progression on PARPi
Number of subjects: 42
Study 37486343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 42
Study 37486363 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated responsivity of brain regions implicated in reward valuation to thin models
Number of subjects: 146
Study 37486363 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated responsivity of brain regions implicated in reward valuation to high-calorie binge foods
Number of subjects: 146
Study 37486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy combined with partial splenic embolization (EP group)
Number of subjects: 110
Study 37486372 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic therapy alone (E group)
Number of subjects: 110
Study 37486616 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy targeting CD19 and/or CD22
Number of subjects: 134
Study 37486633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed nicotine patches
Number of subjects: 0
Study 37486633 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37486650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Iron supplementation
Number of subjects: 0
Study 37486650 — intervention group
Group type: COMPARATOR
Intervention: Oral Iron supplementation
Number of subjects: 0
Study 37486652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 1 mg once
Number of subjects: 73
Study 37486652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 37486732 — intervention group
Group type: EXPERIMENTAL
Intervention: PC4L system (intervention group)
Number of subjects: 558
Study 37486732 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 558
Study 37486738 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable biosensor (Wrist Angel) monitoring physiological signals (pulse, electrodermal activity, skin temperature, acceleration) for 8 weeks.
Number of subjects: 18
Study 37486738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interviews and questionnaires at baseline, weeks 4, 7, and 8.
Number of subjects: 18
Study 37486755 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital live seminar (2.5-hour midwife-assisted, included exercises on empathy and clear communication)
Number of subjects: 657
Study 37486755 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based application (fully automated, 9 consecutive training lessons with same content as live seminar)
Number of subjects: 657
Study 37486755 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 657
Study 37486759 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Companion Program Plus (SCP Plus)
Number of subjects: 114
Study 37486770 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for injury risk
Number of subjects: 450
Study 37486770 — intervention group
Group type: COMPARATOR
Intervention: Not using a prediction model
Number of subjects: 450
Study 37486775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 4 mg daily
Number of subjects: 7769
Study 37486775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7769
Study 37486952 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified balanced energy-protein (BEP) supplementation and iron-folic acid (IFA) tablets
Number of subjects: 1897
Study 37486952 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid (IFA) alone
Number of subjects: 1897
Study 37487056 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + AI
Number of subjects: 270
Study 37487056 — intervention group
Group type: COMPARATOR
Intervention: AI alone
Number of subjects: 270
Study 37487144 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) in PORTEC-1 trial
Number of subjects: 880
Study 37487144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT) in PORTEC-2 trial
Number of subjects: 880
Study 37487144 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy in PORTEC-1 trial
Number of subjects: 880
Study 37487144 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT) in PORTEC-2 trial
Number of subjects: 880
Study 37487169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) once every 3 weeks
Number of subjects: 32
Study 37487169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) once every 3 weeks + Radiotherapy (RT)
Number of subjects: 32
Study 37487433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced PCD-CT scans measuring CT-values of the blood pool on 70 keV VMI series.
Number of subjects: 329
Study 37487656 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging with positron emission tomography (PET) using tracers
Number of subjects: 1000
Study 37487656 — intervention group
Group type: COMPARATOR
Intervention: Coronary CT angiography (CTA)
Number of subjects: 1000
Study 37487677 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi survey criteria for IMCU admission
Number of subjects: 81
Study 37487677 — intervention group
Group type: COMPARATOR
Intervention: Delphi survey round 1
Number of subjects: 81
Study 37487677 — intervention group
Group type: COMPARATOR
Intervention: Delphi survey round 2
Number of subjects: 81
Study 37487677 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria classification
Number of subjects: 81
Study 37487677 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of specialty and institution type
Number of subjects: 81
Study 37487682 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound assessment of venous congestion (IVC, HV, PV, IRV)
Number of subjects: 350
Study 37487764 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent BMI
Number of subjects: 95
Study 37487764 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent income
Number of subjects: 95
Study 37487764 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education
Number of subjects: 95
Study 37488191 — intervention group
Group type: EXPERIMENTAL
Intervention: Samuraciclib (360 mg once daily)
Number of subjects: 81
Study 37488191 — intervention group
Group type: EXPERIMENTAL
Intervention: Samuraciclib monotherapy in TNBC
Number of subjects: 81
Study 37488191 — intervention group
Group type: EXPERIMENTAL
Intervention: Samuraciclib in combination with fulvestrant
Number of subjects: 81
Study 37488286 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib (CF cohort, n=28)
Number of subjects: 48
Study 37488286 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib (CU cohort, n=12)
Number of subjects: 48
Study 37488286 — intervention group
Group type: COMPARATOR
Intervention: physician's therapy of choice (RWS cohort, n=8)
Number of subjects: 48
Study 37488287 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-L1 blockade with adebrelimab (two doses before surgery)
Number of subjects: 30
Study 37488287 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-L1 blockade with adebrelimab
Number of subjects: 30
Study 37488289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2-overexpressing metastatic breast cancer (n=72)
Number of subjects: 177
Study 37488289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (n=74)
Number of subjects: 177
Study 37488289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2 non-expressing metastatic breast cancer (n=40)
Number of subjects: 177
Study 37488289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2 non-expressing metastatic breast cancer with ERBB2 expression below the median (n=14)
Number of subjects: 177
Study 37488289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2 non-expressing metastatic breast cancer with ERBB2 expression above the median (n=10)
Number of subjects: 177
Study 37488291 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Number of subjects: 10
Study 37488349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae Plane Block (ESPB)
Number of subjects: 80
Study 37488349 — intervention group
Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 80
Study 37488368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve Advance Care Planning (ACP) during the COVID pandemic
Number of subjects: 20
Study 37488446 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-OHOA (sodium 2-hydroxyoleate) at a maximum tolerated dose (MTD) of 12,000 mg/daily
Number of subjects: 54
Study 37488448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment
Number of subjects: 108
Study 37488472 — intervention group
Group type: EXPERIMENTAL
Intervention: Former preterm-born adolescents
Number of subjects: 1491
Study 37488472 — intervention group
Group type: COMPARATOR
Intervention: Term-born adolescents
Number of subjects: 1491
Study 37488472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (term and preterm)
Number of subjects: 1491
Study 37488580 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta infusions <90 min
Number of subjects: 2678
Study 37488580 — intervention group
Group type: COMPARATOR
Intervention: Agalsidase beta infusions ≥90 min
Number of subjects: 2678
Study 37488580 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rates
Number of subjects: 2678
Study 37488580 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients <30 kg
Number of subjects: 2678
Study 37488580 — intervention group
Group type: COMPARATOR
Intervention: Patients ≥30 kg
Number of subjects: 2678
Study 37488580 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-agalsidase beta antibody-positive patients
Number of subjects: 2678
Study 37488588 — intervention group
Group type: EXPERIMENTAL
Intervention: MT-assisted ambulation up to three times daily, guided by the Johns Hopkins Mobility Goal Calculator, until hospital discharge or after 10 days.
Number of subjects: 0
Study 37488588 — intervention group
Group type: EXPERIMENTAL
Intervention: MT-assisted ambulation
Number of subjects: 0
Study 37488588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study 37488627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0
Study 37488627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound therapy
Number of subjects: 0
Study 37488627 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured counseling
Number of subjects: 0
Study 37488627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0
Study 37488627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two treatments (from the above options)
Number of subjects: 0
Study 37488627 — intervention group
Group type: COMPARATOR
Intervention: Single treatment (from the above options)
Number of subjects: 0
Study 37488632 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA implementation led by district health managers
Number of subjects: 85
Study 37488734 — intervention group
Group type: EXPERIMENTAL
Intervention: holo beta-lactoglobulin lozenge (holoBLG) 2x daily for 3 months
Number of subjects: 35
Study 37488811 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg at weeks 0 and 4)
Number of subjects: 352
Study 37488811 — intervention group
Group type: COMPARATOR
Intervention: Apremilast (30 mg twice daily)
Number of subjects: 352
Study 37488811 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to risankizumab after 16 weeks of apremilast
Number of subjects: 352
Study 37488811 — intervention group
Group type: COMPARATOR
Intervention: Continuing apremilast after 16 weeks
Number of subjects: 352
Study 37489066 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg, tremelimumab 75 mg, cisplatin 80 mg/m²
Number of subjects: 16
Study 37489066 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab with tremelimumab and chemotherapy
Number of subjects: 16
Study 37489096 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgency syndrome
Number of subjects: 247
Study 37489096 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with sleep
Number of subjects: 247
Study 37489096 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health
Number of subjects: 247
Study 37489096 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical aspects of QoL
Number of subjects: 247
Study 37489096 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological aspects of QoL
Number of subjects: 247
Study 37489374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus treatment
Number of subjects: 0
Study 37489724 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR)
Number of subjects: 5054
Study 37489744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly (Cuvitru®; Baxalta US, Inc.; part of Takeda, MA, U.S.A.)
Number of subjects: 75
Study 37489818 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelets plus standard care
Number of subjects: 17541
Study 37489819 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA approved drugs matched to genomic targets
Number of subjects: 0
Study 37489819 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA approved drugs used outside their approved indications
Number of subjects: 0
Study 37489991 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-derived body composition measurements from LDCT scans
Number of subjects: 0
Study 37489991 — intervention group
Group type: COMPARATOR
Intervention: Cox proportional hazards models without AI-derived body composition measurements
Number of subjects: 0
Study 37489992 — intervention group
Group type: EXPERIMENTAL
Intervention: US and MRI fusion-targeted biopsies with systematic random prostate biopsies
Number of subjects: 0
Study 37489992 — intervention group
Group type: COMPARATOR
Intervention: Systematic random prostate biopsies alone
Number of subjects: 0
Study 37490017 — intervention group
Group type: EXPERIMENTAL
Intervention: VRRS HomeKit (teleneuro-VRRS group)
Number of subjects: 40
Study 37490017 — intervention group
Group type: COMPARATOR
Intervention: Usual territorial rehabilitative treatments (UTRTs; control group)
Number of subjects: 40
Study 37490069 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMR (Histologic Endoscopic Mucosal Remission)
Number of subjects: 0
Study 37490069 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMI (Histologic Endoscopic Mucosal Improvement) without HEMR
Number of subjects: 0
Study 37490069 — intervention group
Group type: COMPARATOR
Intervention: HEMR and HEMI
Number of subjects: 0
Study 37490079 — intervention group
Group type: EXPERIMENTAL
Intervention: FPIA PET
Number of subjects: 10
Study 37490085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (90 mg/kg/d) and clavulanate (6.4 mg/kg/d) for 10 days (n=254)
Number of subjects: 515
Study 37490085 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days (n=256)
Number of subjects: 515
Study 37490085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin and clavulanate
Number of subjects: 515
Study 37490086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 544
Study 37490086 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 544
Study 37490100 — intervention group
Group type: EXPERIMENTAL
Intervention: Back pain model
Number of subjects: 452
Study 37490100 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability model
Number of subjects: 452
Study 37490202 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0
Study 37490202 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 0
Study 37490202 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 0
Study 37490202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37490268 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL/BDP PAD-cream
Number of subjects: 0
Study 37490291 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human prourokinase (rhPro-UK)
Number of subjects: 663
Study 37490291 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 663
Study 37490292 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ctDNA testing with next-generation sequencing (NGS) assay before lung cancer diagnosis
Number of subjects: 150
Study 37490292 — intervention group
Group type: COMPARATOR
Intervention: Standard tissue genotyping after tissue diagnosis (reference cohort)
Number of subjects: 150
Study 37490292 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ctDNA testing
Number of subjects: 150
Study 37490292 — intervention group
Group type: COMPARATOR
Intervention: Tissue NGS
Number of subjects: 150
Study 37490337 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital physical therapy (home exercise, education, CBT, device with movement digitalization, asynchronous monitoring)
Number of subjects: 82
Study 37490337 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (in-person exercises, manual therapy, education, CBT)
Number of subjects: 82
Study 37490337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (digital and conventional)
Number of subjects: 82
Study 37490459 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cup
Number of subjects: 436
Study 37490459 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 436
Study 37490604 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored polyethylene glycol and sulfate solution (FPSS)
Number of subjects: 500
Study 37490604 — intervention group
Group type: COMPARATOR
Intervention: Oral sulfate solution (OSS)
Number of subjects: 500
Study 37490604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FPSS and OSS
Number of subjects: 500
Study 37490693 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking Aldosterone Synthesis
Number of subjects: 0
Study 37490738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored communication messages from healthcare workers
Number of subjects: 0
Study 37490738 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 37490742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package (diagnostic tests, diagnostic algorithm, training-and-communication package)
Number of subjects: 1718
Study 37490742 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 1718
Study 37490742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 1718
Study 37490745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 761)
Number of subjects: 1512
Study 37490916 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL therapy
Number of subjects: 0
Study 37490939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin (40 mg)
Number of subjects: 42
Study 37490939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 37490981 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (TH)
Number of subjects: 847
Study 37490981 — intervention group
Group type: COMPARATOR
Intervention: In-person (IP)
Number of subjects: 847
Study 37491084 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based virtual reality relaxation (S-VR) using 360° panoramic video content and music relaxation intervention through a VR device for ±10 minutes plus standard care
Number of subjects: 80
Study 37491084 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based virtual reality relaxation (S-VR)
Number of subjects: 80
Study 37491084 — intervention group
Group type: COMPARATOR
Intervention: Guided imagery relaxation therapy in the form of a leaflet plus standard care
Number of subjects: 80
Study 37491088 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (10 mg/kg/d for 8 days)
Number of subjects: 72
Study 37491104 — intervention group
Group type: EXPERIMENTAL
Intervention: efavaleukin alfa
Number of subjects: 0
Study 37491104 — intervention group
Group type: EXPERIMENTAL
Intervention: rozibafusp alfa
Number of subjects: 0
Study 37491104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37491149 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop spinal cord stimulation
Number of subjects: 134
Study 37491149 — intervention group
Group type: COMPARATOR
Intervention: Open-loop spinal cord stimulation
Number of subjects: 134
Study 37491196 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor pain intensity (measured by A-LPQ subscale on birthing pain)
Number of subjects: 880
Study 37491196 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased blood loss during delivery (for every 10ml change)
Number of subjects: 880
Study 37491196 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of shoulder dystocia
Number of subjects: 880
Study 37491196 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of pethidine for labor analgesia
Number of subjects: 880
Study 37491196 — intervention group
Group type: EXPERIMENTAL
Intervention: Having nausea during menstruation before current pregnancy (sometimes)
Number of subjects: 880
Study 37491199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap balancing technique
Number of subjects: 225
Study 37491199 — intervention group
Group type: COMPARATOR
Intervention: Measured resection technique
Number of subjects: 225
Study 37491216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemental health services (components delivered via telephonic or other communication technology for outreach and consultation/coping skills; in-person for intake/assessment and crisis response)
Number of subjects: 500